Drugs / SA4Ag
SA4Ag
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02364596 | Jan → Feb 2015 | staphylococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01643941 | Aug 2012 → May 2013 | staphylococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01364571 | Aug 2011 → Jan 2013 | staphylococcus aureus infection | Pfizer | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02388165 Comparator | Jul 2015 → Jun 2019 | — | Pfizer | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SA4Ag | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02388165 ↗ |
| Known as | S. aureus 4-antigen vaccine | “The investigational S. aureus 4-antigen vaccine (SA4Ag), comprising capsular polysaccharide serotypes 5 and 8 (CP5 and CP8) conjugated to CRM197, recombinant mutant clumping...” PMID 31993453 ↗ Dec 2019 |
| Known as | Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine | “Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine” NCT02388165 ↗ |
| Modality | Vaccine | “A prophylactic Staphylococcus aureus four-antigen vaccine (SA4Ag)” PMID 27916408 ↗ Dec 2016 |
| Route | Intramuscular | “Subjects receive 1 intramuscular injection (0.5 mL) of the low dose level of the SA4Ag vaccine.” NCT01364571 ↗ |